Methylene blue

Methylene blue (methylthioninium chloride) is a synthetic phenothiazine dye with a history that predates pharmaceutical science — it was first synthesized as a textile dye in 1876, and its use in medicine began in the 1890s when Paul Ehrlich demonstrated its affinity for nerve tissue. It is a redox-active molecule that can exist in an oxidized (blue) and reduced (colorless) form and is capable of donating and accepting electrons, which underlies both its primary clinical application and its proposed mechanisms in off-label contexts.¹

In clinical medicine, methylene blue functions as an electron carrier that can reduce methemoglobin back to functional hemoglobin via the NADPH-methemoglobin reductase pathway. In the supplement and biohacking communities, methylene blue is used as an oral supplement with proposed benefits for mitochondrial function, cognitive performance, and neuroprotection — mechanisms postulated to involve its action as an alternative electron carrier in the mitochondrial respiratory chain, its inhibition of nitric oxide synthase and monoamine oxidase, and various antioxidant properties. The evidence base for these proposed benefits in humans is preliminary.¹

Methylene blue injection (IV, prescription drug): FDA-approved for the treatment of pediatric and adult patients with acquired methemoglobinemia — a condition in which hemoglobin is oxidized to a non-oxygen-carrying form, often from drug or toxic chemical exposure (dapsone, nitrites, benzocaine, and others).¹ FDA initial approval: 2016 (for branded IV formulation Provayblue; other IV formulations also approved).

Oral methylene blue (supplement form): Oral methylene blue — typically sold as a 1% USP-grade solution for human consumption — is not FDA-approved for any indication. Products sold for oral use are marketed as supplements and are not reviewed by the FDA for safety or efficacy for any proposed use.

FDA-approved IV use: 1 mg/kg administered intravenously over 5–30 minutes. A repeat dose of up to 1 mg/kg may be given one hour after the first dose if methemoglobin levels remain elevated or symptoms persist. This is a clinical emergency use administered in a healthcare setting, not self-administered.¹

Oral supplement use (off-label, not FDA-approved): Clinical studies exploring cognitive, neuroprotective, or mitochondrial effects have used a wide range of doses — from approximately 0.5 mg/kg to 4 mg/kg — with no consensus optimal dose established. A commonly cited starting point in the biohacking community is approximately 0.5–1 mg/kg. These uses are investigational; no dose has been established as safe and effective for any oral indication.

Intravenous (FDA-approved clinical use). Oral solution (supplement use, not FDA-approved).

Methylene blue solutions should be stored at room temperature, protected from light. The solution is intensely blue and will stain skin, mucous membranes, urine (urine will appear blue or green), and clothing on contact — this is expected and harmless. Medical-grade IV formulations must be kept sterile.¹

Serotonin syndrome — critical drug interaction: Methylene blue is a potent MAO inhibitor and should not be used concomitantly with serotonergic drugs, including SSRIs (fluoxetine, sertraline, etc.), SNRIs (venlafaxine, duloxetine, etc.), MAOIs, opioids, or other serotonergic agents. Serious or fatal serotonin syndrome has been reported when methylene blue was administered IV to patients on serotonergic medications. This is a boxed warning for the FDA-approved IV formulation and is equally applicable to oral use.¹

Additional considerations:¹

• G6PD deficiency: Paradoxically, methylene blue can worsen methemoglobinemia and cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency — a genetic enzyme deficiency that impairs the NADPH pathway methylene blue depends on for its methemoglobin-reducing action. G6PD status should be considered before use.
• Dosing and toxicity: At high doses, methylene blue itself can oxidize hemoglobin and cause methemoglobinemia, creating a biphasic dose-response that limits its safe dose range.
• Urine and skin discoloration: Blue-green urine and temporary blue staining of skin and mucous membranes are expected pharmacological effects, not adverse events.
• Supplement quality: Oral supplement products vary considerably in quality, concentration, and purity. USP-grade 1% methylene blue sold for human consumption is not subject to the same manufacturing standards as FDA-approved pharmaceutical products. Individuals using oral methylene blue should use only pharmaceutical-grade products from verified sources.
• Pregnancy and lactation: Safety data are inadequate for use during pregnancy or breastfeeding.